ArticleAmerican journal of physiology. Heart and circulatory physiology2011
Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair.
Article in American journal of physiology. Heart and circulatory physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- The influence of SDF-1 (CXCL12) gene in health and disease: a review of literature.Biophysical reviews · 2025Review
- Inflammation and vascular remodeling in COVID-19 hearts.Angiogenesis · 2023Article
- Synergistic effect of VEGF and SDF-1α in endothelial progenitor cells and vascular smooth muscle cells.Frontiers in pharmacology · 2022Article
- Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study.Frontiers in veterinary science · 2021Article
- Hypoxic Preconditioning Enhances Cellular Viability and Pro-angiogenic Paracrine Activity: The Roles of VEGF-A and SDF-1a in Rat Adipose Stem Cells.Frontiers in cell and developmental biology · 2020Article
- Review
- Autologous serum supplement favours in vitro regenerative paracrine factors synthesis.Cell proliferation · 2017Article
- sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts: differential roles in cell growth, energy metabolism, and extracellular matrix remodeling.American journal of physiology. Cell physiology · 2016Article
- Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts.American journal of physiology. Cell physiology · 2015Article
- Paracrine action of mesenchymal stem cells revealed by single cell gene profiling in infarcted murine hearts.PloS one · 2015Article
- Cardiac regeneration and diabetes.Regenerative medicine research · 2014Review
- Enhancing the efficacy of mesenchymal stem cell therapy.World journal of stem cells · 2014Review
- Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention.American journal of physiology. Cell physiology · 2014Article
- Article
- Stem cell therapy independent of stemness.World journal of stem cells · 2012Article
- Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.American journal of physiology. Cell physiology · 2012Article
- Local activation of cardiac stem cells for post-myocardial infarction cardiac repair.Journal of cellular and molecular medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The skeletal muscle is endowed with an impressive ability to regenerate after injury, and this ability is coupled to paracrine production of many trophic factors possessing cardiovascular benefits. Taking advantage of this humoral capacity of the muscle, we recently demonstrated an extracardiac therapeutic regimen based on intramuscular delivery of VEGF-A(165) for repair of the failing hamster heart. This distal organ repair mechanism activates production from the injected hamstring of many trophic factors, among which stromal-derived factor-1 (SDF1) prominently mobilized multi-lineage progenitor cells expressing CXCR4 and their recruitment to the heart. The mobilized bone marrow progenitor cells express the cardiac transcription factors myocyte enhancer factor 2c and GATA4 and several major trophic factors, most notably IGF1 and VEGF. SDF1 blockade abrogated myocardial recruitment of CXCR4(+) and c-kit(+) progenitor cells with an insignificant effect on the hematopoietic progenitor lineage. The knockdown of cardiac progenitor cells led to deprivation of myocardial trophic factors, resulting in compromised cardiomyogenesis and angiogenesis. However, the VEGF-injected hamstring continued to synthesize cardioprotective factors, contributing to moderate myocardial tissue viability and function even in the presence of SDF1 blockade. These findings thus uncover two distinct but synergistic cardiac therapeutic mechanisms activated by intramuscular VEGF. Whereas the SDF1/CXCR4 axis activates the progenitor cell cascade and its trophic support of cardiomyogenesis intramuscularly, VEGF amplifies the skeletal muscle paracrine cascade capable of directly promoting myocardial survival independent of SDF1. Given that recent clinical trials of cardiac repair based on the use of marrow-mobilizing agents have been disappointing, the proposed dual therapeutic modality warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.